

Approved



**Namibia**  
**Country Operational Plan**  
**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		101,897		101,897	597,102	698,999
USAID		11,045,147	0	11,045,147	9,254,854	20,300,001
PC		425,600		425,600	790,400	1,216,000
HHS/CDC	1,487,500	7,210,852		8,698,352	10,001,648	18,700,000
HHS/HRSA		300,000		300,000	0	300,000
State/AF		85,000		85,000	0	85,000
<b>Total</b>	<b>1,487,500</b>	<b>19,168,496</b>	<b>0</b>	<b>20,655,996</b>	<b>20,644,004</b>	<b>41,300,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						On Hold Amount	Total
	State	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC		152,389	0			13,475	0	165,864
HBHC		183,122	0	1,463	25,000	151,956	0	361,541
HKID				2,194		2,559,129	0	2,561,323
HLAB		174,684					0	174,684
HTXS	0	2,380,148	300,000			5,471,473	0	8,151,621
HVAB		221,590					0	221,590
HVCT		87,747	0			297,266	0	385,013
HVMS	101,897	2,437,423		421,943		1,920,600	0	4,881,863
HVOP	0	26,173			30,000	13,475	0	69,648
HVSI	0	640,289	0			101,168	0	741,457
HVTB		356,749	0			128,607	0	485,356
MTCT		474,057	0			13,475	0	487,532

Approved



OHSS	0	240,533	0	0		53,535	0	<b>294,068</b>
PDCS		238,334	0			136,562	0	<b>374,896</b>
PDTX		1,085,114	0		30,000	184,426	0	<b>1,299,540</b>
	<b>101,897</b>	<b>8,698,352</b>	<b>300,000</b>	<b>425,600</b>	<b>85,000</b>	<b>11,045,147</b>	<b>0</b>	<b>20,655,996</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	25,001	0
HKID	2,515,467	0
HVTB	0	
PDCS	60,076	0
<b>Total Technical Area Planned Funding:</b>	<b>2,600,544</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	0	0
HVSI	0	0
OHSS	0	0
<b>Total Technical Area Planned Funding:</b>	<b>0</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	0	0
HVCT	210,774	0
HVOP	30,000	0
MTCT	0	0
<b>Total Technical Area Planned Funding:</b>	<b>240,774</b>	<b>0</b>

#### Technical Area: Treatment

Approved



Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	6,750,000	0
PDTX	667,347	0
<b>Total Technical Area Planned Funding:</b>	<b>7,417,347</b>	<b>0</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2018
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,593
	Number of new ANC and L&D clients	22,122
	By: Known positives at entry	2,808
	By: Number of new positives identified	1,106
	Sum of Positives Status disaggregates	3,914
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNU's ONLY): <15	
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNU's ONLY): 50+	
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	35,164
	Number of new ANC and L&D clients	37,233
	By: Known positives at entry	3,591
	By: Number of new positives identified	1,617
	Sum of Positives Status disaggregates	5,208
	Required only for DREAMS countries - By known positives: <15	
	Required only for DREAMS countries - By known positives: 15-19	
	Required only for DREAMS countries - By known positives: 20-24	
	Required only for DREAMS countries - By new positives: <15	
	Required only for DREAMS countries - By new positives: 15-19	
	Required only for DREAMS countries - By new positives: 20-24	
	Required only for DREAMS countries - Denominator: <15	



	Required only for DREAMS countries - Denominator: 15-19	
	Required only for DREAMS countries - Denominator: 20-24	
	Required only for DREAMS countries - Denominator: 25-49	
	Required only for DREAMS countries - Denominator: 50+	
	Required only for DREAMS countries - By known positives: 25-49	
	Required only for DREAMS countries - By known positives: 50+	
	Required only for DREAMS countries - By new positives: 25-49	
	Required only for DREAMS countries - By new positives: 50+	
	By Age (DREAMS SNUs ONLY): <15	
	By Age (DREAMS SNUs ONLY): 15-19	
	By Age (DREAMS SNUs ONLY): 20-24	
	By Age (DREAMS SNUs ONLY): 25-49	
	By Age (DREAMS SNUs ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	



	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,593
	New on ART	1,009
	Already on ART at beginning of current pregnancy	2,509
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	35,164
	New on ART	1,508
	Already on ART at beginning of current pregnancy	3,066
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	34,746
	By Age: 0-60 days	0
	By Age: 2 months - 9 years	0
	By Age: 10-14	0
	By Age: 15-19	12,093
	By Age: 20-24	12,427
	By Age: 25-29	10,226
	By Age: 30-49	0
	By Age: 50+	0



	Sum of age disaggregates (Prior to FY15)	24,520
	Sum of age disaggregates (FY15-Current)	34,746
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	34,746
	By circumcision technique: Device-based VMMC	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population	119,281



	who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	
	Total number of people in the target population	758,302
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	



	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	466
	Aggregated Age/sex: 15+ Male	32,327
	Aggregated Age/sex: <15 Female	849
	Aggregated Age/sex: 15+ Female	81,139
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,800
	Total estimated number of key population in the catchment area	176,000
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	250
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	550



	the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,000
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	5,000
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	11,000
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	160,000



	population in the catchment area)	
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	163,027
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex:	



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,114
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	42,206
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,778
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	102,292
	Test Result by Aggregated Age and Sex: Negative <15 Male	72
	Test Result by Aggregated Age and Sex: Negative 15+ Male	448
	Test Result by Aggregated Age and Sex: Negative <15 Female	53
	Test Result by Aggregated Age and Sex: Negative 15+ Female	661
	Test Result by Aggregated Age and Sex: Positive <15 Male	281
	Test Result by Aggregated Age	3,209



	and Sex: Positive 15+ Male	
	Test Result by Aggregated Age and Sex: Positive <15 Female	383
	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,114
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	5,048
	Service Delivery Point (Community): Homebased testing	53,049
	Service Delivery Point (Community): Mobile testing	6,978
	Service Delivery Point (Community): Other	7,826
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility):	6,121



	Inpatient	
	Service Delivery Point (Facility): Outpatient	38,350
	Service Delivery Point (Facility): Pediatric	1,995
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	16,326
	Service Delivery Point (Facility): VMMC	906
	Service Delivery Point (Facility): PMTCT	18,207
	Service Delivery Point (Facility): TB Clinics	3,063
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	



	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	127,867
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	



	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex:	



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,440
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	28,614
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,264
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	86,242
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age	482



	and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,372
	Test Result by Aggregated Age and Sex: Positive <15 Female	411
	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,746
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community)	



	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	15,419
	Service Delivery Point (Facility): Outpatient	67,283
	Service Delivery Point (Facility): Pediatric	4,408
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	3,319
	Service Delivery Point (Facility): PMTCT	30,250
	Service Delivery Point (Facility): TB Clinics	3,004
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by	



	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
	TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.
Number of registered new and relapsed TB cases with		3,038



	documented HIV status, during the reporting period.	
	Total number of registered new and relapsed TB cases, during the reporting period.	3,180
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and	



	relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	180
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	1,634



	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	114
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,109
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB	



	cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,581
	Total number of registered new and relapsed TB cases, during the reporting period.	5,865
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49	



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	318
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,980
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	278
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,005
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and	



	relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,200
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	761
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	1,065
	Sum of Age/Sex disaggregates	1,826
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
Required only for DREAMS		



	countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS	



	countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS	



	countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and	



	sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and	



	sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS	



	countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	5,319
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	8,055
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and	



	sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,700
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By age/sex: 18-24 Male	
	By age/sex: 25+ Male	
	Age/Sex: 18+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By age/sex: 18-24 Female	
	By age/sex: 25+ Female	
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support	



	Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Education Support Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Social Protection Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	



	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Education Support 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18	



	Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Program 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Other Service Areas 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Social Protection 1-9 Female	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,009
	The number of registered new and relapse TB cases with documented	1,035



	HIV-positive status during TB treatment during the reporting period	
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	35
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	564
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	388
	On ART: Already on ART	



	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,626
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,822
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and	



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	<p>Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male &lt;15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	<p>192</p>
	<p>Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	<p>1,378</p>
	<p>Aggregated Age/Sex: Female &lt;15 (Numerator: The number of</p>	<p>121</p>



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	935
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	19,453
	Screened for TB by Age/Sex:<15 Male	973
	Screened for TB by Age/Sex: 15+ Male	8,752
	Screened for TB by Age/Sex:<15 Female	973
	Screened for TB by Age/Sex: 15+ Female	8,754
	Screen Result: Screened Positive for TB	726
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	



	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	726
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	34
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	19
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	442
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	849
	Screened for TB by Age/Sex: <15 Male	42
	Screened for TB by Age/Sex: 15+ Male	382
	Screened for TB by Age/Sex: <15 Female	42
	Screened for TB by Age/Sex: 15+ Female	383
	Screen Results: Screened Positive for TB	34
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	34
	[Sub-disagg of Specimen Sent]	1



	Diagnostic Test: Smear Only	
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	32
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	1,365
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,353
	Sum of Infant Age disaggregates	2,718
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	27
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	



	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	18
	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	3,068
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,414
	Sum of Infant Age disaggregates	4,482
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	86
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	



	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	74
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	80,658
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	3,127
	Aggregated Age/Sex: 15+ Male	28,497
	Aggregated Age/Sex: <15 Female	3,349
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	45,686
	Sum of Aggregated Age/Sex <15	6,476
	Sum of Aggregated Age/Sex 15+	74,183
	Sum of Aggregated Age/Sex disaggregates	80,659
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
Age/Sex: 50+ Male		



	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	94,485
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	3,015
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	29,320
	Aggregated Age/Sex: <15 Female	3,356
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	58,619
	Sum of Aggregated Age/Sex <15	6,371
	Sum of Aggregated Age/Sex 15+	87,939
	Sum of Aggregated Age/Sex disaggregates	94,310
	Age/Sex: <1	
Age/Sex: 1-9		
Age/Sex: 10-14 Male		



	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	13,294
	By Age/Sex: <1	0
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	256
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex:	4,564



	15+ Male	
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	269
	Aggregated Grouping by Age/Sex: 15+ Female	8,207
	Sum of Aggregated Age/Sex disaggregates	13,296
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,899
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
By Age/Sex: 25-49 Female		



	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	0
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	48
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	4,213
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	60
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	8,578
	Sum of Aggregated Age/Sex disaggregates	12,899
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records	22,335



	and /or supporting laboratory results within the past 12 months.	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	
	Numerator: Indication: Routine	19,232
	Numerator: Indication: Targeted	2,987
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication:	



	15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by	



	Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by	



	Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	717
	Numerator Aggregated Age/Sex: 15+ Male	8,351
	Numerator Aggregated Age/Sex: <15 Female	717
	Numerator Aggregated Age/Sex: 15+ Female	11,377
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex:	



	15+ Female	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	35
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	



	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	



	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	20
	Numerator: Indication: Targeted	15
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	



	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	



	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	1
	Numerator Aggregated Age/Sex: 15+ Male	14



	Numerator Aggregated Age/Sex: <15 Female	1
	Numerator Aggregated Age/Sex: 15+ Female	19
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,269
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,761
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator:	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female	



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	213
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,199
	Aggregated Age/Sex: <15 Female	222



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,615
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	252
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,363
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	265
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated	7,883



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,687
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	13,146
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,827
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	39
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	7,792



	initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	42
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,294
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	54
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,758
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate	



	and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	CD4: Number of laboratories that participate in this PT program	20
	CD4: Number of laboratories that perform this testing	20
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that perform this testing	1
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	7
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	8
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	8
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
	HIV viral load: Number of	2



	laboratories that participate in this PT program	
	HIV viral load: Number of laboratories that perform this testing	8
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	27
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	31
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	31
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	21
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	22
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	22
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1

Approved





## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
6459	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	85,000
7443	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	0
9872	Potentia Namibia Recruitment Consultancy	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9876	Namibia Institute of Pathology	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9940	Development Aid from People to People, Namibia	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10181	U.S. Peace Corps	Other USG	U.S. Peace Corps	GHP-State	0



		Agency			
10389	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
10397	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	0
10780	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12752	Ministry of Health and Social Services, Namibia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13207	Polytechnic of Namibia	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13227	ITECH	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
13601	Society for Family	NGO	U.S. Agency for	GHP-State	0



	Health		International Development		
13752	Project HOPE	NGO	U.S. Agency for International Development	GHP-State	2,070,774
14390	University of Namibia	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14391	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16756	Ministry of Health and Social Services, Namibia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16771	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16829	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0



17529	JHPIEGO	University	U.S. Agency for International Development	GHP-State	400,000
17531	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	2,000,000
17532	University of North Carolina	University	U.S. Agency for International Development	GHP-State	0
17560	PharmAccess	NGO	U.S. Agency for International Development	GHP-State	1
18035	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,000,000
18036	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18037	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
18039	United Nations Children's Fund	Multi-lateral Agency	U.S. Department of Health and Human	GHP-State	0



			Services/Centers for Disease Control and Prevention		
18040	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18088	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	400,000
18126	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	0
18354	TBD	TBD	Redacted	Redacted	Redacted
18355	TBD	TBD	Redacted	Redacted	Redacted
18356	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18357	TBD	TBD	Redacted	Redacted	Redacted
18358	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	437,347
18359	UNAIDS - Joint	Multi-lateral	U.S. Department	GHP-State	0



	United Nations Programme on HIV/AIDS	Agency	of Health and Human Services/Centers for Disease Control and Prevention		
18360	New Partner	TBD	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	300,000
18362	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18400	TBD	TBD	Redacted	Redacted	Redacted
18401	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	800,000
18402	TBD	TBD	Redacted	Redacted	Redacted
18404	Population Council	NGO	U.S. Agency for International Development	GHP-State	0
18420	TBD	TBD	Redacted	Redacted	Redacted
18430	U.S. Department of Health and Human Services/Centers for Disease Control and	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0

Approved



	Prevention (HHS/CDC)		Prevention		
--	-------------------------	--	------------	--	--



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 6459</b>	<b>Mechanism Name: Department of State/African Affairs</b>
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 85,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 85,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	85,000

### Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Focus Area:	Post GBV Care

### Budget Code Information

<b>Mechanism ID:</b> 6459			
<b>Mechanism Name:</b> Department of State/African Affairs			
<b>Prime Partner Name:</b> U.S. Department of State			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	25,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	30,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	30,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 7443</b>	<b>Mechanism Name: Supply Chain Management System (SCMS)</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 7443			
<b>Mechanism Name:</b> Supply Chain Management System (SCMS)			
<b>Prime Partner Name:</b> Partnership for Supply Chain Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 9872	<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS002722
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Potentia Namibia Recruitment Consultancy	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 9872			
<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS002722			
<b>Prime Partner Name:</b> Potentia Namibia Recruitment Consultancy			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 9876	<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS002058
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Namibia Institute of Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount



GHP-State	0
-----------	---

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 9876			
<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS002058			
<b>Prime Partner Name:</b> Namibia Institute of Pathology			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	20
LAB_PT_TA	CD4: Number of laboratories that perform this testing	20
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories	7



	that achieve acceptable successful passing criteria in this PT program	
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	8
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	8
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	2
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	8
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	27
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	31
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	31
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	21
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	22
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	22
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1



**Implementing Mechanism Details**

<b>Mechanism ID: 9940</b>	<b>Mechanism Name: Cooperative Agreement 1U2GPS0018665166</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Development Aid from People to People, Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	9940		
<b>Mechanism Name:</b>	Cooperative Agreement 1U2GPS0018665166		
<b>Prime Partner Name:</b>	Development Aid from People to People, Namibia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	74,831
PP_PREV_DSD	Total number of people in the target population	111,999
PP_PREV_DSD	Aggregated Age/sex: <15 Male	416
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	30,902
PP_PREV_DSD	Aggregated Age/sex: <15 Female	799
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	42,714
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	55,519
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,017
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	16,543
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,872
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	35,087



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,889
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	51,630
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	55,519
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative <15 Male	72
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative 15+ Male	448
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative <15 Female	53
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative 15+ Female	661
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	68
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,055
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	55
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,751
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	53,049

**Implementing Mechanism Details**

<b>Mechanism ID: 10181</b>	<b>Mechanism Name: PEACE CORPS NAMIBIA</b>
Funding Agency: PC	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	0
-----------	---

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	10181		
<b>Mechanism Name:</b>	PEACE CORPS NAMIBIA		
<b>Prime Partner Name:</b>	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,950
PP_PREV_DSD	Total number of people in the target population	3,950
PP_PREV_DSD	Aggregated Age/sex: <15 Male	50
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	1,925
PP_PREV_DSD	Aggregated Age/sex: <15 Female	50
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,925
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,350
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,350
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	2,700



	HIV/AIDS	
--	----------	--

**Implementing Mechanism Details**

<b>Mechanism ID: 10389</b>	<b>Mechanism Name: Systems to Improve Access to Pharmaceuticals and Services</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	10389		
<b>Mechanism Name:</b>	Systems to Improve Access to Pharmaceuticals and Services		
<b>Prime Partner Name:</b>	Management Sciences for Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10397</b>	<b>Mechanism Name: Challenge TB Fund</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 1,200,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,200,000</b>	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>10397</b>
<b>Mechanism Name:</b>	<b>Challenge TB Fund</b>
<b>Prime Partner Name:</b>	<b>KNCV Tuberculosis Foundation</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,765
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	123
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	580
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	84
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	408
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	207
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	988
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,195
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	54
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	292
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	36
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	208
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,767
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	261

HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	94
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	75
HTC_TST_TA	Sum of Aggregated Age/Sex <15	14
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	169
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	183
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	4
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	40
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	3
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	29
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	261
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,028
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,094
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	116
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,045
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	74
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	792



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	261
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	264
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	136
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	104

**Implementing Mechanism Details**

<b>Mechanism ID: 10780</b>	<b>Mechanism Name: Cooperative Agreement 1U58PS001452</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 10780			
<b>Mechanism Name:</b> Cooperative Agreement 1U58PS001452			
<b>Prime Partner Name:</b> University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 12752	<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS003014
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Services, Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 12752			
<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS003014			
<b>Prime Partner Name:</b> Ministry of Health and Social Services, Namibia			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 13207	<b>Mechanism Name:</b> Cooperative Agreement 1U2GPS002902
----------------------------	---



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Polytechnic of Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 13207</b>			
<b>Mechanism Name: Cooperative Agreement 1U2GPS002902</b>			
<b>Prime Partner Name: Polytechnic of Namibia</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13227</b>	<b>Mechanism Name: I-TECH: Support to MOHSS</b>
----------------------------	---



	<b>National Health Training Center (NHTC)</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: ITECH	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13227		
<b>Mechanism Name:</b>	I-TECH: Support to MOHSS National Health Training Center (NHTC)		
<b>Prime Partner Name:</b>	ITECH		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13601</b>	<b>Mechanism Name: Strengthening HIV Prevention for Key Populations</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Society for Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 1,600,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,600,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13601			
<b>Mechanism Name:</b> Strengthening HIV Prevention for Key Populations			
<b>Prime Partner Name:</b> Society for Family Health			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,800
KP_PREV_DSD	Total estimated number of key population in the catchment area	176,000
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	250
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	550
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,000
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	5,000
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	11,000
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	160,000
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	6,669



	months	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	21
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,182
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	26
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,775
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	47
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,957
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,004
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	232
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	3
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	430
HTC_TST_DSD	Service Delivery Point (Community): Other	5,546
HTC_TST_DSD	Service Delivery Point (Facility): VCT	723
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	300
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	45
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	255
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	300
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	300
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	300
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	45
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	255
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	300



TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	210
TX_PVLS_DSD	Numerator: Indication: Routine	105
TX_PVLS_DSD	Numerator: Indication: Targeted	105
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	32
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	178
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	264
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	300
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	222
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	45
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	255

### Implementing Mechanism Details

<b>Mechanism ID: 13752</b>	<b>Mechanism Name: Adherence &amp; Retention Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Project HOPE	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,070,774</b>	
<b>Applied Pipeline Amount: 330,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,400,774</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,070,774

**Cross-Cutting Budget Attribution(s)**

Economic Strengthening	400,000
Gender: Gender Equality	115,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: GBV	40,500
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID: 13752</b>			
<b>Mechanism Name: Adherence &amp; Retention Project</b>			
<b>Prime Partner Name: Project HOPE</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	1,860,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	210,774	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	14,024
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,001
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,696
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,004
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	6,334
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,005
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	11,030



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	13,035
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	29
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	249
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	48
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	259
HTC_TST_DSD	Service Delivery Point (Community): Index testing	5,048
HTC_TST_DSD	Service Delivery Point (Community): Other	2,280
HTC_TST_DSD	Service Delivery Point (Facility): VCT	5,973
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,200
OVC_SERV_DSD	Age/Sex: 18+ Male	761
OVC_SERV_DSD	Age/Sex: 18+ Female	1,065
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,826
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	5,319
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	8,055

**Implementing Mechanism Details**

<b>Mechanism ID: 14390</b>	<b>Mechanism Name: Cooperative Agreement U2GGH001182</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 150,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 150,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

Approved



GHP-State	0
-----------	---

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14390		
<b>Mechanism Name:</b>	Cooperative Agreement U2GGH001182		
<b>Prime Partner Name:</b>	University of Namibia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 14391	<b>Mechanism Name:</b> University of California-San Francisco
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

Approved



GHP-State	0
-----------	---

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14391		
<b>Mechanism Name:</b>	University of California-San Francisco		
<b>Prime Partner Name:</b>	University of California at San Francisco		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16756</b>	<b>Mechanism Name: Improving the Quality of Namibia's Essential Health Services and Systems (IQ-NEHSS)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Services, Namibia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 2,052,000</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 2,052,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16756		
<b>Mechanism Name:</b>	Improving the Quality of Namibia's Essential Health Services and Systems (IQ-NEHSS)		
<b>Prime Partner Name:</b>	Ministry of Health and Social Services, Namibia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,380
PMTCT_ART_DSD	New on ART	499
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,157
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,609
PMTCT_ART_TA	New on ART	705



PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,757
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,380
PMTCT_STAT_DSD	Number of new ANC and L&D clients	10,314
PMTCT_STAT_DSD	By: Known positives at entry	1,101
PMTCT_STAT_DSD	By: Number of new positives identified	615
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,716
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,609
PMTCT_STAT_TA	Number of new ANC and L&D clients	18,672
PMTCT_STAT_TA	By: Known positives at entry	1,746
PMTCT_STAT_TA	By: Number of new positives identified	741
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,487
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	41,556
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,063
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,754
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,228
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	28,513
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,291
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	37,267
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	41,558
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	65
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	724



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	89
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,171
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	3,508
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	27,577
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,755
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	7,758
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	958
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	69,463
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,389
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,454
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,767
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	47,862
HTC_TST_TA	Sum of Aggregated Age/Sex <15	7,156
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	62,316
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	69,472
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	401
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,278
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	274
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,338
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	11,184
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	39,614



HTC_TST_TA	Service Delivery Point (Facility): Pediatric	2,304
HTC_TST_TA	Service Delivery Point (Facility): VMMC	158
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	14,457
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,755
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	232
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	235
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	17
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	122
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	81
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,230
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	3,440
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	195
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,688
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	175
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number	1,172



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	88
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	88
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	48
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,310
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,310
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	78
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The	673



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	491
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,057
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	377
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,434
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	25
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	11
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,359
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	713
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,072
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	41
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	36
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	24,295
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	643
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,460
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	613



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	16,579
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,256
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	23,039
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	24,295
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	61,607
TX_CURR_TA	Aggregated Age/Sex: <15 Male	2,262
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	16,719
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2,564
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	40,062
TX_CURR_TA	Sum of Aggregated Age/Sex <15	4,826
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	56,781
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	61,607
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,012
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,405
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,607
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,012
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,492
TX_NEW_TA	Aggregated Grouping by Age: <1	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	2,472
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	6,020
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	8,492
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,319
TX_RET_DSD	Total number of adults and children who initiated ART	4,852

	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,561
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,758
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,331
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,521
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,978
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,961
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,357
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,621
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	0



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,645
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,318

**Implementing Mechanism Details**

<b>Mechanism ID: 16771</b>	<b>Mechanism Name: Namibia Mechanism for Public Health Assistance, Capacity, and Technical Support (NAM-PHACTS)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 500,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b>	16771		
<b>Mechanism Name:</b>	Namibia Mechanism for Public Health Assistance, Capacity, and		
<b>Prime Partner Name:</b>	Technical Support (NAM-PHACTS)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16829</b>	<b>Mechanism Name: Health Financing and Governance</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 300,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 16829			
<b>Mechanism Name:</b> Health Financing and Governance			
<b>Prime Partner Name:</b> Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17529	<b>Mechanism Name:</b> Maternal and Child Survival Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 400,000	
<b>Applied Pipeline Amount:</b> 1,200,000	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 1,600,000	
Funding Source	Funding Amount
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

Water	22,000
Human Resources for Health	78,526



**Budget Code Information**

<b>Mechanism ID: 17529</b>			
<b>Mechanism Name: Maternal and Child Survival Program</b>			
<b>Prime Partner Name: JHPIEGO</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	155,467	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	44,533	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	200,000	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	28,500
PP_PREV_DSD	Total number of people in the target population	461,500
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	24,500
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,978
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,240
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,340
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	6,580
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,580
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	149
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	149
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	6,978

### Implementing Mechanism Details

<b>Mechanism ID: 17531</b>	<b>Mechanism Name: USAID HIV Clinical Services Technical Assistance Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,000,000</b>	
<b>Applied Pipeline Amount: 1,800,000</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 3,800,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,000,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	325,769
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b> 17531			
<b>Mechanism Name:</b> USAID HIV Clinical Services Technical Assistance Project			
<b>Prime Partner Name:</b> IntraHealth International, Inc			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,000,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,530
PMTCT_ART_DSD	New on ART	439
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,234
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,530
PMTCT_STAT_DSD	Number of new ANC and L&D clients	10,055
PMTCT_STAT_DSD	By: Known positives at entry	1,563
PMTCT_STAT_DSD	By: Number of new positives identified	405
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,968
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,646
PMTCT_STAT_TA	Number of new ANC and L&D clients	1,722
PMTCT_STAT_TA	By: Known positives at entry	314
PMTCT_STAT_TA	By: Number of new positives identified	90



PMTCT_STAT_TA	Sum of Positives Status disaggregates	404
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	21,138
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	393
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,963
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,697
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,788
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,090
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	17,751
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	19,841
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	37
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	221
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	90
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	951
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,539
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	7,825
HTC_TST_DSD	Service Delivery Point (Facility): VCT	247
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	8,920
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	239
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	17,768
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	686
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION	4,287



	ONLY: 15+ Male	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	931
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,548
HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,617
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	14,835
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	16,452
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	40
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	479
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	53
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	762
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	1,563
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	9,960
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	1,470
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	381
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	614
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	640
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	332



TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	264
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	100
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	104
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	53
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	44
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	19,453
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	973
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	8,752



TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	973
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	8,754
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	726
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	726
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	34
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	19
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	442
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	849
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	42
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	382
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	42
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	383
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	34
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	34
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	1
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	32
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	308
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	976
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,284
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	2

PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	7
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	51
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	211
PMTCT_EID_TA	Sum of Infant Age disaggregates	262
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	3
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	30,934
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,086
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12,444
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,086
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	16,319
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,172
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	28,763
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	30,935
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,213
TX_CURR_TA	Aggregated Age/Sex: <15 Male	42
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	486
TX_CURR_TA	Aggregated Age/Sex: <15 Female	42
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	643
TX_CURR_TA	Sum of Aggregated Age/Sex <15	84
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,129
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,213
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,292
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	151
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,731



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	153
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,259
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,294
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	262
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	9
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	105
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	9
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	139
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	262
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	21,775
TX_PVLS_DSD	Numerator: Indication: Routine	18,922
TX_PVLS_DSD	Numerator: Indication: Targeted	2,737
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	717
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	8,263
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	717
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	10,901
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	35
TX_PVLS_TA	Numerator: Indication: Routine	20
TX_PVLS_TA	Numerator: Indication: Targeted	15
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	1
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	14
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	1
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	19
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,698
TX_RET_DSD	Total number of adults and children who initiated ART	4,203



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	138
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,485
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	138
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,927
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	148
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,722
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	149
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,186



TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	26
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	30
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	16



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	---	--

**Implementing Mechanism Details**

<b>Mechanism ID: 17532</b>	<b>Mechanism Name: Measure Evaluation Phase 4</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 300,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17532</b>			
<b>Mechanism Name: Measure Evaluation Phase 4</b>			
<b>Prime Partner Name: University of North Carolina</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Prevention	HVOP	0	0
------------	------	---	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17560</b>	<b>Mechanism Name: Country Partnership to Increase Access to Integrated HIV/AIDS and Health Services Using Mobile Health Services to Reach Underserved Populations in Namibia</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: PharmAccess	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17560
<b>Mechanism Name:</b>	Country Partnership to Increase Access to Integrated HIV/AIDS and Health Services Using Mobile Health Services to Reach Underserved
<b>Prime Partner Name:</b>	Health Services Using Mobile Health Services to Reach Underserved



Populations in Namibia PharmAccess			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18035</b>	<b>Mechanism Name: Namibia Mechanism for Public Health Assistance, Capacity, and Technical Support (NAM-PHACTS)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,000,000</b>	
<b>Applied Pipeline Amount: 993,312</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,993,312</b>	
Funding Source	Funding Amount
GHP-State	2,000,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	18035		
<b>Mechanism Name:</b>	Namibia Mechanism for Public Health Assistance, Capacity, and		
<b>Prime Partner Name:</b>	Technical Support (NAM-PHACTS)		
	University of Washington		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,800,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	200,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,683
PMTCT_ART_DSD	New on ART	71
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	118
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,909
PMTCT_ART_TA	New on ART	803
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,309
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,683
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,753
PMTCT_STAT_DSD	By: Known positives at entry	144
PMTCT_STAT_DSD	By: Number of new positives identified	86



PMTCT_STAT_DSD	Sum of Positives Status disaggregates	230
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,909
PMTCT_STAT_TA	Number of new ANC and L&D clients	16,839
PMTCT_STAT_TA	By: Known positives at entry	1,531
PMTCT_STAT_TA	By: Number of new positives identified	786
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,317
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	13,796
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	0
VMMC_CIRC_DSD	By Age: 15-19	5,767
VMMC_CIRC_DSD	By Age: 20-24	4,881
VMMC_CIRC_DSD	By Age: 25-29	3,148
VMMC_CIRC_DSD	By Age: 30-49	0
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	10,648
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	13,796
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	13,796
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,868
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	143
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,252
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	386
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	4,087



	ONLY: 15+ Female	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	529
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	6,339
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,868
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	8
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	110
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	11
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	190
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,074
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	2,948
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	240
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	906
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	1,529
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	171
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,636
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	365
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,873
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,566
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	27,832
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,931
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	37,705
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	40,636
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15	41

	Male	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	615
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	84
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,646
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	2,672
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	17,709
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	2,104
HTC_TST_TA	Service Delivery Point (Facility): VMMC	3,161
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	14,323
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	667
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	778
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	851
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	47
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	467
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	28
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	236
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,090
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,161
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of	110

	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,156
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	95
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	729
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	307
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	307
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	184
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	94
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	1,216



	during TB treatment during the reporting period	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,408
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	112
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	652
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	52
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	400
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,658
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	490
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,148
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	45
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	35
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	24,629
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,398
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,468
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,650



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	12,113
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,048
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	21,581
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	24,629
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	31,665
TX_CURR_TA	Aggregated Age/Sex: <15 Male	711
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	12,115
TX_CURR_TA	Aggregated Age/Sex: <15 Female	750
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	17,914
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,461
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	30,029
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	31,490
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,190
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	105
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,303
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	116
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,666
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,190
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,145
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	39
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,636
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	51
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	2,419
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	4,145
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,548
TX_RET_DSD	Total number of adults and children who initiated ART	2,906



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	75
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,054
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	84
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,335
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	104
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,185
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	116
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,501



TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,683
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,155
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,460
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,157
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,637
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	53
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	2,424



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	---	--

**Implementing Mechanism Details**

<b>Mechanism ID: 18036</b>	<b>Mechanism Name: Cooperative Agreement UGH000710</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18036		
<b>Mechanism Name:</b>	Cooperative Agreement UGH000710		
<b>Prime Partner Name:</b>	African Society for Laboratory Medicine		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18037</b>	<b>Mechanism Name: HRSA/I-TECH</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18037		
<b>Mechanism Name:</b>	HRSA/I-TECH		
<b>Prime Partner Name:</b>	University of Washington		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18039</b>	<b>Mechanism Name: UNICEF</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18039		
<b>Mechanism Name:</b>	UNICEF		
<b>Prime Partner Name:</b>	United Nations Children's Fund		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0

### Implementing Mechanism Indicator Information

Approved



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18040</b>	<b>Mechanism Name: WHO</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18040</b>			
<b>Mechanism Name: WHO</b>			
<b>Prime Partner Name: World Health Organization</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0

**Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18088</b>	<b>Mechanism Name: 4Children</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	100,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	18088		
<b>Mechanism Name:</b>	4Children		
<b>Prime Partner Name:</b>	Catholic Relief Services		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Care	HKID	400,000	0
------	------	---------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18126</b>	<b>Mechanism Name: AIDSFree</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 900,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 900,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18126		
<b>Mechanism Name:</b>	AIDSFree		
<b>Prime Partner Name:</b>	John Snow Inc (JSI)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,518
VMMC_CIRC_DSD	By Age: 15-19	5,000
VMMC_CIRC_DSD	By Age: 20-24	5,000
VMMC_CIRC_DSD	By Age: 25-29	2,518
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	10,000
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	12,518
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	12,518

### Implementing Mechanism Details

Mechanism ID: 18354	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18355	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 18356	Mechanism Name: Technical Assistance to
---------------------	---



	<b>provide High Quality VMMC</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 607,104</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 607,104</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18356		
<b>Mechanism Name:</b>	Technical Assistance to provide High Quality VMMC		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention	8,432



	program within the reporting period	
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	0
VMMC_CIRC_DSD	By Age: 15-19	1,326
VMMC_CIRC_DSD	By Age: 20-24	2,546
VMMC_CIRC_DSD	By Age: 25-29	4,560
VMMC_CIRC_DSD	By Age: 30-49	0
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	3,872
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	8,432
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	8,432
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0

### Implementing Mechanism Details

<b>Mechanism ID: 18357</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18358</b>	<b>Mechanism Name: EGPAF</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 437,347</b>	
<b>Applied Pipeline Amount: 62,653</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	437,347



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18358</b>			
<b>Mechanism Name: EGPAF</b>			
<b>Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	437,347	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18359</b>	<b>Mechanism Name: UNAIDS</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 18359			
<b>Mechanism Name:</b> UNAIDS			
<b>Prime Partner Name:</b> UNAIDS - Joint United Nations Programme on HIV/AIDS			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 18360	<b>Mechanism Name:</b> Quality Improvement and Capacity for Impact Project (QICIP)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 300,000	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 300,000	
Funding Source	Funding Amount
GHP-State	300,000



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18360 <b>Mechanism Name:</b> Quality Improvement and Capacity for Impact Project (QICIP) <b>Prime Partner Name:</b> New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18362	<b>Mechanism Name:</b> Association of Public Health laboratories (APHL)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18362			
<b>Mechanism Name:</b> Association of Public Health laboratories (APHL)			
<b>Prime Partner Name:</b> Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18400	<b>TBD:</b> Yes
REDACTED	

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18401	<b>Mechanism Name:</b> Global Health Supply Chain-Procurement Supply Management
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:



<b>Total All Funding Sources: 800,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 800,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	800,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18401		
<b>Mechanism Name:</b>	Global Health Supply Chain-Procurement Supply Management		
<b>Prime Partner Name:</b>	Global Health Supply Chain Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	800,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

Approved



<b>Mechanism ID: 18402</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18404</b>	<b>Mechanism Name: Project SOAR</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18404</b>			
<b>Mechanism Name: Project SOAR</b>			
<b>Prime Partner Name: Population Council</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18420</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18430</b>	<b>Mechanism Name: CDC Namibia</b>
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 18430</b>
----------------------------



<b>Mechanism Name:</b> CDC Namibia			
<b>Prime Partner Name:</b> U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		140,562		100,333	140,562	240,895
ICASS		438,254		199,170	438,254	637,424
Institutional Contractors				0	0	0
Management Meetings/Professional Development		106,868		42,317	106,868	149,185
Non-ICASS Administrative Costs		431,830		233,997	431,830	665,827
Staff Program		489,447	0	90,631	489,447	580,078



Travel						
USG Staff Salaries and Benefits - Internationally Recruited		1,038,736	0	212,371	1,038,736	1,251,107
USG Staff Salaries and Benefits - Locally Recruited		978,675	0	196,035	978,675	1,174,710
<b>Total</b>	<b>0</b>	<b>3,624,372</b>	<b>0</b>	<b>1,074,854</b>	<b>3,624,372</b>	<b>4,699,226</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		84,802		0	84,802	84,802
Computers/IT Services		124,419		0	124,419	124,419
ICASS		850,765		0	850,765	850,765
Institutional Contractors		1,278,683		481,769	1,278,683	1,760,452
Management Meetings/Professional		63,500		0	63,500	63,500



Development						
Non-ICASS Administrative Costs		0		1,533,774	0	1,533,774
Non-ICASS Motor Vehicles		58,000		0	58,000	58,000
Peace Corps Volunteer Costs		5,001		0	5,001	5,001
Staff Program Travel		298,354		386,579	298,354	684,933
USG Staff Salaries and Benefits - Internationally Recruited	1,487,500	428,559		0	1,916,059	1,916,059
USG Staff Salaries and Benefits - Locally Recruited		1,565,879		0	1,565,879	1,565,879
<b>Total</b>	<b>1,487,500</b>	<b>4,757,962</b>	<b>0</b>	<b>2,402,122</b>	<b>6,245,462</b>	<b>8,647,584</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		0		14,000	0	14,000



ICASS		101,897		0	101,897	101,897
Management Meetings/Professional Development		0		48,000	0	48,000
Non-ICASS Administrative Costs		0		130,000	0	130,000
Peace Corps Volunteer Costs				6,000	0	6,000
Staff Program Travel		0		48,000	0	48,000
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		0		351,102	0	351,102
<b>Total</b>	<b>0</b>	<b>101,897</b>	<b>0</b>	<b>597,102</b>	<b>101,897</b>	<b>698,999</b>

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
-------------------------------	-----	-----------	-----------	------------------	-------	---

Approved



Indirect Costs		0		150,000	0	150,000
Peace Corps Volunteer Costs		400,000		300,000	400,000	700,000
Staff Program Travel				46,000	0	46,000
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		25,600		294,400	25,600	320,000
<b>Total</b>	<b>0</b>	<b>425,600</b>	<b>0</b>	<b>790,400</b>	<b>425,600</b>	<b>1,216,000</b>